Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea Indeed, How can something that NEVER STARTED, be continuing ???
no sens here!
?
LOLOL
FOR THOSE INTERESTED IN THE TRUTH
here s the July 8-K (SEC CURRENT FILLING)
http://ih.advfn.com/p.php?pid=nmona&article=43656247
NO more 4020 since July!!!
Yup, and considering its a very slow day (all over The Pink Sheets and other market) It s not bad at all!!!
Here, you have a better look at them
http://www.tradingmarkets.com/print/news/press-release/mres_nrobf_neuro-biotech-discloses-its-list-of-licenses-1195434.html
NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
Posted on: Tue, 28 Sep 2010 12:04:00 EDT
Symbols: MRES, NROBF
BASEL, Switzerland, Sept 28, 2010 /PRNewswire via COMTEX/ --
Neuro-Biotech Corporation (PINKSHEETS: MRES | PowerRating) (OTCQB: MRES) discloses its list of licenses.
NEURO # 1
SymPath(R)
TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME, DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE STATES AND ANXIOUS DISORDERS.
NEURO # 2
AXIS(TM)
TO QUANTITATIVELY AND DIRECTLY EVALUATE THE HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.
NEURO # 3
TETRIC(TM)
TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE & INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.
NEURO #4 and #5
ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE OUT THE CLINICAL PREDOMINENCE
NEURO # 6
TRYPTYR
TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.
NEURO #7
DIVAN
TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.
NEURO # 8
GACHA
TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE CELLULAR ENERGETIC CAPACITY.
NEURO # 9
FREERAD
TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN REGARDS TO THE AXIS ACTIVITY.
NEURO # 10
MAOS
TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND THERAPEUTIC APPROACHES.
NEURO # 11
NEURENDOM
TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
NEURO # 12
NEURENDOF
TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
SOURCE Neuro-Biotech Corp.
REDAY for an OTHER great day for MRES !!!
GO GO
Well, I wrote here info@neuro-agora.com and got an answered the next day.
yup, 700% UP SINCE !!!
nobody can say bad about that FACT!
Haha, same here, my broker call me 3 times and was all exited, he wanted me to sell to have a good before Christmas commission. He was disappointed when a said , no not before next year LOL !!
I really think that this time it is the good one!!! Next year this Baby will learn to FLYYYY !lol
WOW, NICE DAY !!! 11 304 100 Volume and 32% UP...
I lIKE
41X the 10 day average !!! impressive
Isnt that great!!, and all that before Christmas when the market is a bit slower than usual. For me MRES will BLOW in January...
GO MRES
MRES is UP BY 700% In the past 2 month ans a half!!!
it is speaking by itself !
Here, you can find them here...
Basicaly some Blood Test and some Neutraceuticals
http://neuro-biotechcorp.com/products.html
All R&D Completed All ready to be sold, one had already been sold in the past...
I think that some of us should realy go back to their book '' Accounting for Dumies'' and to step back to Kindergarten to learn how to read.
When a company stated in a PR that she reimbursed some 'Third Parties' this have NOTHING to do with sells. It is simply an investment of a 'Related Parties' so an investment of a Person or of a Group LINKED to the Company. In addition to that, such affirmation is really serious specialy when the company is publishing every year their AUDITED FINANCIAL STATEMENTS!!!.... Here for reading class!
When a Company have a deficit and that this deficit isnt suported by a Loan, it s like saying that the Company found the liquidity in order to suport it s own deficit.
Finaly when ALL OTHER Company out there are trying to increase their assets to create an artificial Capital Gain, we need to ask ourself WHY in this particular case THIS Company is doing the Complete OPOSITE!!! There most be a real Reason that some person Persistently Negative here DO NOT Understand or DO NO WANT to Understand!!!
I leave you to your reflections!
ROCHE ? ... BOEHRINGER INGELHEIM ? ... WHO EXACTLY IS MOVING BEHIND MRES (NEURO-BIOTECH CORP)?
Beacon has been wondering about Neuro-Biotech Corp. for a while now, but no one can predict moves made by large Pharmaceutical Companies, especially at a time when large players are about to lose some of their main core product Patents. Biotech Companies
(EMAILWIRE.COM, December 13, 2010 ) On March 8, 2010 in Barcelona at the Bio-Europe Spring show, John Carrol wrote “The theme here at BIO-Europe Spring 2010 is a new season for growing collaboration between Big Pharmas and Little Biotechs. http://www.fiercepharma.com/story/pharma-biotech-collaboration-new-black/2010-03-08
In early November this year, Neuro-Biotech announced negotiating with a Major Pharmaceutical. And where about? “In Spain” Coincidence or well planned move?
In 2000, Neuro-Biotech Corp had made an unusual move by filing a form 20 FR 12 G http://www.secinfo.com/dRqWm.511a6.htm#1ry6
After spending $3,000,000 to acquire the IP, and $7 million in R & D?? Why a Company whom had orders worldwide and 21 patents would remove the products out of the Market? Bench Market testing???
9 years later 2 off shore hedge funds invest in a small new Bio-Tech Co., trading on the (OTCQB) under the symbol MRES? Without making any noise, they’ve transferred 16 worldwide sales and manufacturing licenses, and curiously depreciated the assets and took a huge lost in their financials?
Who’s paying for all that??
ROCHE ? ... BOEHRINGER INGELHEIM ? ...
Beacon’s staff analysed the last 90 days trading, and concluded there shouldn’t be that many shares left out there. Why would they do such moves?? Maybe to finance the products go to market, by taking the upswing from shares acquired at very low costs…….
Beacon thinks it makes a lot of sense, so what’s good for them, should be good for our members as well??? Beacon staff spoke to Company management today, and they were not very comfortable in answering some of the key questions, but indicated some answers could come within a few days…. If that’s the plan, the stock could really fly….
Same here, and look yesterday the bid was 0.15 all day with 40 000 volume ( not a lot but it s the most BRWC had in a long time) and today it when up to 0.18 with the same .020 ask and more Volume..
for me that s a good sign ...
Ok earn, straight up, how much public company does this guy suppose to have ?? Every time i turn around, here he is!!! You seem to know a lot about him, so do you know how much?
BIG resistance at 0.0004
Indeed, this newz is clearing saying 'Keep an eye on us, watch us' ...
Welcome aboard Bille,
well you can start whit the short history for Neuro-Biotech
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57145343
this is also a good source of info
http://ih.advfn.com/p.php?pid=nmona&article=45341356
this is a long document but most of it is in it and it s a SEC Document so you cant go wrong whit it. Form 20 F
http://ih.advfn.com/p.php?pid=nmona&article=45341356
But basically, MRES have 16 product whit all the R&D completed (representing Millions of Dollars in investment). 12 revolutionary blood test and 4 neuroceutical. Neuro-Biotech is the only company in the world to have such product and technology. It is representing Billions of Dollars WolrdWide. One of the blood have already been sold in the past, in just a question of time before they hit the market again!!!
That s for sure, BRWC woke up a month ago, after a looooooong time sleeping, there is a reason for sure...
Yup and around 900% UP IN A MONTH!!!
THAT S VERY VERY GOOD...
well dont know for you but i see a NICE UP 33.33%...
not bad at all
MRES Already have sold one of the test and did 5000 clinical study on it...
Neuro-Biotech's first blood test, SymPath has been the subject of more than 5,000 clinical tests and 75,000 units were sold before its voluntary withdrawal from the market. The SymPath is currently the only blood test on the planet which can successfully measure on a scale, recognized by the World Health Organization, (similar to the scale that is used to measure cholesterol) the mental state of a patient and by analogy the physical consequences, thus allowing physicians to carry out a more precise diagnosis. It should also be mentioned that the eighth blood test of our portfolio NeuroChAT is currently the only blood test allowing an early diagnosis of Alzheimer's Disease.
http://ih.advfn.com/p.php?pid=nmona&article=45341356
and
http://www.secinfo.com/dRqWm.511a6.htm
NO more R&D to do...
Now they have 16 product ready to hit the market!!!
NEURO-BIOTECH CORP: A BRIEF HISTORY
PART 1
(part 2 is after)
1. From 1997 to 2000 : The Company was on the Canadian Dealing Network (Vancouver or Calgary Stock Exchange) under the symbol NBIO.
2. On August 1, 2000 The Company filed with the SEC a form 20F in the spirit of a possible listing on NASDAQ. This document can be accessed by following this link: HERE http://www.secinfo.com/dRqWm.511a6.htm
3. Following this document they realized that the Company wasn’t meeting the capitalization norms of NASDAQ.
4. Page 1 of form 20F (Part 1) (Item 1 - Description of the Business) we can see that in 1999, the first test SymPath, was the first patent to be internationally recognized (Canada, US, International)
5. In December 1999 the Company signed a Distribution Agreement for the Middle East for 575 000 tests (Revenues of 3,4 million). An initial delivery of 75 000 was sent on February 2000
6. It is also written that the Company was in the process of developing two other tests.
7. At page 3 of the document, it is written that Neuro-Biotech acquired in 1997 the intellectual property of the technological platform of the tests, for the sum of 3 million dollars from the Laval University.
8. In next pages, we are able to read about all the scientific background :
9. At page 9, the Company, in 1998, has disbursed 1,143 million. In 1999 1,149 million and in 2000 approximately 2,5 million in Research and Development.
10. At page 10, it is written that in 1997 Neuro-Biotech has ordered for Ernst & Young from Toronto (with a cost 350,000$), a Market study for its diagnostic test. Conclusion of this report was positive and that the product is unique.
11. At page 27 of the same report, we are able to see that in 1998, 1999 and 2000, the shares acquired at the beginnings in 1998, at a price of 0,15$, reached in 2000 a price of 2,60$
Conclusion of this first part:
The Company cannot join NASDAQ, causing a major dissension on the board of directors due to the fact that the directors, at that time, wanted to keep the company “closed”, meaning that they wanted to control all the steps from research and development to the sale to the customer.
The scientist behind all those research, Dr. A. G. Roberge, didn’t agree with their point of view and decided to withdraw herself.
Following this withdrawal, legal procedures were taken, and Dr. A. G. Roberge and her team had to disburse a total of 7,5 million dollars in order to regain the intellectual property and the name.
The company then became a shell and had to change its name as well as its operations.
That was in 2000. But the adventure Neuro-Biotech was far from over.
http://neuro-biotechcorp.com/en/site/display/page/166.html
NEURO-BIOTECH CORP: A BRIEF HISTORY
PART 2
1. From 2000 to 2009, Dr . A. G. Roberge and her team have continued the Research and Development. Today, 12 blood tests and 4 Neuroceuticals (Tablets) are available and ready to be commercialized.
2. Between June 2009 and December 2009, 2 Hedge Funds from the Bahamas acquired rights on the intellectual property.
3. In the same period, they acquired the control of a Pink Sheets Company with the status of No Information, and financed all the work in order to bring it to OTCQB.
4. They proceeded to a name change that was approved in June 2010. This document can be downloaded here:
5. On or about April 30 2010, the two Bahamian Hedge Funds signed with Neuro-Biotech Corp. 16 licence agreements for the worldwide manufacturing and distribution agreements, including the right to give sublicenses and those licences were for the 12 blood test and the 4 Neuroceuticals
6. The Company, in July 15, relocated its corporate headquarters to Basel, Switzerland.
7. All those information, were disclosed to the SEC in the form of a 8K on July 19, 2010. This document can be downloaded here:
8. The Company also published an Update to Shareholders in order to explain all the changes incurred: HERE
9. In the first 10Q of the fiscal year 2010-2011, we can clearly see the impact of the decision of the two Hedge Funds regarding the evaluation of the assets in their Financials. Since the 2 Hedge Funds received for their 16 licenses a total of 615 million of shares of the Company and at the date of the transaction, those shares were worth 0.085$ the two Hedge Funds decided, in order not to over evaluate the company, to put at nominal value the value of the shares received for the 16 licenses, creating a deficit of more than 50,000,000 dollars (Note: The first SymPath blood test was evaluated by Ernst&Young at a price of 7,5 million US) (Page 5):
10. On September 15, 2010, the Company disclosed under the form of a 8K the nomination of its new CEO, Dr Claude Poulin, a general practitioner.
11. Following this nomination, the Company started to issue press releases describing the content of its licenses. Every time, the Company was releasing a technical version its was followed later in the day or the morning after by a vulgarized version of the press release: HERE
12. Two things have to be noted in those PR: the company never mentioned any amounts concerning possible revenues at the exception of October 6, 2010 where it releases “ Projected Market Penetration and Revenue Analysis” giving information to shareholders, and letting people make their own calculation, leading them to a number of 14 billion dollars in possible revenues.
13. On November 1st, 2010, the Company releases “Update and Latest Developments.” Where it discloses all the steps, shares issued, and agreements into which the Company has entered since the first Update to Shareholders.
14. On November 10, 2010, the Company releases the list and description of its Neuroceuticals as well as the importance of those products.
In conclusion:
At the fall of year 2010, all products mentioned (16 licenses) are ready to be commercialized, have been tested, and the Research and Development stage has already been completed.
* Another important fact to be noted is that the two Hedge Funds, at the moment of the transfer of the licenses, have also agreed to complete a private placement of 2 million dollars based on a stock price of 0.25$ per share. This information was disclosed in the 8K filed on July 19, 2010.
http://neuro-biotechcorp.com/en/site/display/page/165.html
Neuro-Biotech's first blood test, SymPath has been the subject of more than 5,000 clinical tests and 75,000 units were sold before its voluntary withdrawal from the market. The SymPath is currently the only blood test on the planet which can successfully measure on a scale, recognized by the World Health Organization, (similar to the scale that is used to measure cholesterol) the mental state of a patient and by analogy the physical consequences, thus allowing physicians to carry out a more precise diagnosis. It should also be mentioned that the eighth blood test of our portfolio NeuroChAT is currently the only blood test allowing an early diagnosis of Alzheimer's Disease
.
AN OTHER 10% UP !!!
GO MRES!!!
So the button point is that finally there was nothing here to be exited about, unlike what all the media said or make people believe.
It wasn't right to set the opening prices at 33 instead of 26, and even 26 was in my opinion WAY to hight, should have been around 10, 15 max...
like you said the PPS should be below ford, and it is only around those prices that GM is gonna be a good buy...
see you all there lol
WHAT A GREAT DAY!! UP 20% !!!
And more than 7 000 000 VOLUME !!!
THIS BABY IS BACK TO LIFE !!!!!
NEWZ OUT
NEURO-BIOTECH CORP. RELEASES A LIST OF ANSWERS REGARDING NUMEROUS ENQUIRIES
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Monday 22 November 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) publishes answers to the most frequently asked questions.
The topic commonly asked about is in regards to Company's statements that no further R&D needs to be carried out on the 16 products that have been licensed. This technical platform was bought from a university following 20 years of research for the sum of $3 million. A total of $5 million was spent by the end of 2000 and subsequently, in the last 10 years research and development has yielded 16 products that are ready for production.
Neuro-Biotech's first blood test, SymPath has been the subject of more than 5,000 clinical tests and 75,000 units were sold before its voluntary withdrawal from the market. The SymPath is currently the only blood test on the planet which can successfully measure on a scale, recognized by the World Health Organization, (similar to the scale that is used to measure cholesterol) the mental state of a patient and by analogy the physical consequences, thus allowing physicians to carry out a more precise diagnosis. It should also be mentioned that the eighth blood test of our portfolio NeuroChAT is currently the only blood test allowing an early diagnosis of Alzheimer's Disease.
The Company has stated in its financials such as its 10-Q, that it does not have any employees because everyone works on a contractual basis, and the original agreements are with the two hedge funds who are financing the entire operation. This situation should change in the next few months with the set up and installation of the laboratory.
At the time of the acquisition of the licenses, the Company immediately created a deficit of more than $50 million by depreciating the value of those. In order to answer this recurring issue, the board of directors made this decision to avoid an over evaluation of the Company before it starts generating significant revenues. An independent third party evaluation by a specialized biotech firm is planned by management to assess the Company's assets and make a subsequent move onto a more important exchange. The evaluation by an independent firm specialized in biotech of the Company's assets will be planned when the direction will decide that the Company is in a position to upgrade to a more important exchange.
The Company would also like to point out that for its market penetration plans, Neuro-Biotech is also using the conclusions of a report ordered to the firm Ernst & Young (Toronto) concerning the potential market of its products.
The negotiations with the Spaniards are moving forward and the Company is preparing for two tours in Spain for 2011 with a group of representatives. Both tours will be separate and completely independent as one will be of scientific content while the other one will be focused on the commercial aspects. These tours will probably extend throughout Europe since the Company recently received similar proposals from Germany.
Finally, the Company foresees the receipt of the private placement of $2 million as well as full payment of the debt owed to third parties before the end of this year.
For more information and to view the documents describing the key elements mentioned above, we invite you visit the corporate website
at www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
GREAT DAY, UP AGAIN !! 23%
lets see what Monday brings us !
Good week end all!
Excel Gold Mining Inc., Announces that it has Retained First Canadian Capital Corp, to Provide Strategic Marketing and Investor Relation Services.
Fri Nov 12, 11:14 AM
* Email Story
* IM Story
* Printable View
Excel Gold Mining Inc. (“Excel” or “the Company”) (TSXV: EGM.V) is pleased to announce that it has retained First Canadian Capital Corp. ("First Canadian" or “the consultant”) to provide strategic marketing and investor relations services. Under the terms of the agreement, Excel will pay First Canadian C$6,000 per month for a twelve month initial term and grant 400,000 stock options at an exercise price of C$(0.15). First Canadian will assist the Company in opening productive dialogue with private investors, analysts, brokers, money managers and other financial professionals. The Consultant will focus on generating market awareness among the investment community as Excel continues to follow up on their already successful drill program.
About First Canadian Capital
Based in Toronto and in business for thirteen years, First Canadian Capital Corp. (www.firstcanadiancapital.com) identifies quality assets and undervalued companies with high growth potential. It has assisted numerous North American corporations in gaining exposure and recognition within the global investment community realizing above average returns.
About Excel
Excel Gold Mining is a Canadian based junior exploration company focused on building shareholder wealth through the acquisition and development of strategic assets in mining friendly jurisdictions, particularly in the province of Quebec.
For further information please contact:
Mr. Martin Harvey
Director, Excel Gold Mining Inc.
(514) 844-8770, #101
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Excel Gold Mining Inc., Announces that it has Retained First Canadian Capital Corp, to Provide Strategic Marketing and Investor Relation Services.
Fri Nov 12, 11:14 AM
* Email Story
* IM Story
* Printable View
Excel Gold Mining Inc. (“Excel” or “the Company”) (TSXV: EGM.V) is pleased to announce that it has retained First Canadian Capital Corp. ("First Canadian" or “the consultant”) to provide strategic marketing and investor relations services. Under the terms of the agreement, Excel will pay First Canadian C$6,000 per month for a twelve month initial term and grant 400,000 stock options at an exercise price of C$(0.15). First Canadian will assist the Company in opening productive dialogue with private investors, analysts, brokers, money managers and other financial professionals. The Consultant will focus on generating market awareness among the investment community as Excel continues to follow up on their already successful drill program.
About First Canadian Capital
Based in Toronto and in business for thirteen years, First Canadian Capital Corp. (www.firstcanadiancapital.com) identifies quality assets and undervalued companies with high growth potential. It has assisted numerous North American corporations in gaining exposure and recognition within the global investment community realizing above average returns.
About Excel
Excel Gold Mining is a Canadian based junior exploration company focused on building shareholder wealth through the acquisition and development of strategic assets in mining friendly jurisdictions, particularly in the province of Quebec.
For further information please contact:
Mr. Martin Harvey
Director, Excel Gold Mining Inc.
(514) 844-8770, #101
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
UP AGAIN TODAY !!!
UP TODAY !!!